Cite
Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open‐Label, Single‐Dose, Parallel‐Group Study.
MLA
Bhardwaj, Rajinder, et al. “Rimegepant 75 Mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open‐Label, Single‐Dose, Parallel‐Group Study.” Clinical Pharmacology in Drug Development, vol. 12, no. 8, Aug. 2023, pp. 790–800. EBSCOhost, https://doi.org/10.1002/cpdd.1244.
APA
Bhardwaj, R., Ivans, A., Stringfellow, J., Morris, B., Coric, V., Croop, R., & Bertz, R. (2023). Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open‐Label, Single‐Dose, Parallel‐Group Study. Clinical Pharmacology in Drug Development, 12(8), 790–800. https://doi.org/10.1002/cpdd.1244
Chicago
Bhardwaj, Rajinder, Andrea Ivans, Joseph Stringfellow, Beth Morris, Vladimir Coric, Robert Croop, and Richard Bertz. 2023. “Rimegepant 75 Mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open‐Label, Single‐Dose, Parallel‐Group Study.” Clinical Pharmacology in Drug Development 12 (8): 790–800. doi:10.1002/cpdd.1244.